SCHEMBL2428089

SCHEMBL2428089

CCCCCCCCCCCCCCCC(=O)N(CC(N)=O)C(=O)CCCCCCCCCCCCCCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
FAAH O00519 1/20 0.50
TP53 P04637 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
CES2 O00748 3/20 0.46
CES1 P23141 3/20 0.46
KDM4E B2RXH2 2/20 0.46
GPR84 Q9NQS5 7/20 0.45
PPARG P37231 6/20 0.45
PPARD Q03181 6/20 0.45
PPARA Q07869 6/20 0.45
HDAC11 Q96DB2 5/20 0.45
TSHR P16473 4/20 0.45
ALDH1A1 P00352 2/20 0.45
TLR2 O60603 2/20 0.45
TDP1 Q9NUW8 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5574516 1.00 SOAT1 (0.50) SOAT1MEN1KMT2AFAAHTP53
SCHEMBL29422232 1.00 SOAT1 (0.50) SOAT1MEN1KMT2AFAAHTP53
SCHEMBL28984571 1.00 SOAT1 (0.50) SOAT1MEN1KMT2AFAAHTP53
SCHEMBL1864976 0.90 FAAH (0.69) SOAT1MEN1KMT2AFAAHTP53
SCHEMBL2335481 0.90 FAAH (0.69) SOAT1MEN1KMT2AFAAHTP53
SCHEMBL29637717 0.87 GPR84 (0.50) SOAT1MEN1KMT2AFAAHTP53
SCHEMBL28925137 0.82 SOAT1 (0.48) SOAT1MEN1KMT2AFAAHTP53
SCHEMBL17272316 0.82 GPR84 (0.58) MEN1KMT2AGPR84PPARGPPARD
SCHEMBL29037394 0.82 GPR84 (0.58) MEN1KMT2AGPR84PPARGPPARD
SCHEMBL2052582 0.82 GPR84 (0.58) MEN1KMT2AGPR84PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055374-A Lipid compounds and compositions for tissue-specific delivery of active substances 韩国生命工学研究院 2026-05-15 CN claimed
CN-119661831-A Compositions and methods for targeted RNA delivery 维乎医疗有限公司 2025-03-21 CN claimed
EP-4326235-A2 CATIONIC LIPIDS AND COMPOSITIONS THEREOF Generation Bio Co. (US) 2024-02-28 EP claimed
CN-115957187-A Lipid nanoparticle composition and drug delivery system prepared from same 北京启辰生生物科技有限公司 2023-04-14 CN claimed
CN-119661831-A Compositions and methods for targeted RNA delivery 维乎医疗有限公司 2025-03-21 CN disclosed
CN-115484932-B Compositions and methods for targeted RNA delivery 维乎医疗有限公司 2024-12-10 CN disclosed
WO-2024151673-A2 RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-07-18 WO disclosed
WO-2024151687-A1 GENETIC SWITCHES AND THEIR USE IN TREATING CANCER FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2024-07-18 WO disclosed
WO-2024151685-A1 RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2024-07-18 WO disclosed
EP-4399307-A2 HBB-MODULATING COMPOSITIONS AND METHODS Flagship Pioneering Innovations VI, LLC (US) 2024-07-17 EP disclosed
EP-4399309-A2 SERPINA-MODULATING COMPOSITIONS AND METHODS Flagship Pioneering Innovations VI, LLC (US) 2024-07-17 EP disclosed
EP-4399306-A2 PAH-MODULATING COMPOSITIONS AND METHODS Flagship Pioneering Innovations VI, LLC (US) 2024-07-17 EP disclosed
WO-2010057150-A1 RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS ENZON PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
EP-2131848-A2 COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALY ACTIVE MOLECULES Merck & Co., Inc. (US) 2009-12-16 EP disclosed
EP-2104740-A2 LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES Sirna Therapeutics, Inc. (US) 2009-09-30 EP disclosed
WO-2008147438-A2 LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES SIRNA THERAPEUTICS, INC. (US) 2008-12-04 WO disclosed
WO-2008103276-A2 COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALY ACTIVE MOLECULES MERCK & CO., INC. (US) 2008-08-28 WO disclosed
EP-1922300-A2 CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM Sirna Therapeutics Inc. (US) 2008-05-21 EP disclosed
WO-2007086883-A2 CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM SIRNA THERAPEUTICS, INC. (US) 2007-08-02 WO disclosed
WO-2007086881-A2 CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM SIRNA THERAPEUTICS, INC. (US) 2007-08-02 WO disclosed